Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease. Series A-2 led by Hatteras Venture Partners and Biohaven. Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors.
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
March 01, 2021